Related Experiment Video
Updated: Sep 28, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
New Adjunct Therapy for Elevated Lipid Levels
1Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch:diane.aschenbrenner@gmail.com .
Insights
Inclisiran (Leqvio) is a new injectable treatment for adults with high cholesterol. It is approved for patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease who need further LDL cholesterol reduction.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Familial hypercholesterolemia and atherosclerotic cardiovascular disease increase cardiovascular risk.
- Elevated low-density lipoprotein cholesterol (LDL-C) is a primary driver of cardiovascular disease.
- Maximal statin therapy does not adequately reduce LDL-C in all patients.
Purpose of the Study:
- To introduce Inclisiran (Leqvio) as an approved adjunct therapy.
- To highlight its role in managing LDL-C in specific adult patient populations.
Main Methods:
- Inclisiran is administered subcutaneously.
- Treatment is intended as an adjunct to diet and statin therapy.
Main Results:
- Inclisiran provides additional reduction in LDL-C.
- It is approved for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease.
Conclusions:
- Inclisiran offers a new therapeutic option for patients requiring further LDL-C lowering.
- The subcutaneous administration by a healthcare provider ensures proper delivery.
Abstract:
Inclisiran (Leqvio) has been approved as adjunct therapy, along with diet and statin therapy, to treat adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional reduction in low-density lipoprotein cholesterol despite maximal statin therapy.Inclisiran is administered subcutaneously by a nurse or other health care provider.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Heart Failure VI: Adjunct Therapies
Hypertension IV: Drug Therapy and Lifestyle Modifications
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Angina IV: Management

